← Eichor
Condition: Tnbc Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Tnbc

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After NAC in TNBC
Phase 2 · 1 location(s) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · NCT04501523QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBC
Phase 2 · 1 location(s) · Fudan University · NCT06786026Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Phase 3 · 306 location(s) · Merck Sharp & Dohme LLC · NCT06393374Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer
Phase 3 · 1 location(s) · Fudan University · NCT05806060Functional Precision Oncology to Predict, Prevent, and Treat Early Metastatic Recurrence of TNBC
Phase 2 · 1 location(s) · University of Utah · NCT05464082A Phase Ib Study of Novel Combination (New) of Low Dose Oral CyclophoSphamide (s) to Potentiate Axatilimab (A) + Retifan
Phase 1 · 1 location(s) · M.D. Anderson Cancer Center · NCT06959537a Single-arm, Single-center, Open Clinical Study
Phase N/A · 1 location(s) · Beijing Geekgene Technology Co., LTD · NCT06431100A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
Phase 2 · 13 location(s) · Processa Pharmaceuticals · NCT06568692LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cance
Phase 2 · 1 location(s) · Fudan University · NCT06387628Role of the Immune Environment in Response to Therapy in Breast Cancer
Phase N/A · 1 location(s) · Abramson Cancer Center at Penn Medicine · NCT05396612A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
Phase 3 · 1 location(s) · Qilu Pharmaceutical Co., Ltd. · NCT06732323Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck
Phase 1 · 48 location(s) · AbbVie · NCT05005403Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK
Phase 2 · 9 location(s) · Swiss Cancer Institute · NCT06358573Granzyme B-PET: Predicting Immunotherapy Efficacy in TNBC
Phase N/A · 1 location(s) · Fudan University · NCT07705438QUEEN-APPLE: A Single-Arm, Multicenter, Prospective Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in
Phase 2 · 1 location(s) · Jiangsu Cancer Institute & Hospital · NCT07601178NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial
Phase 2 · 1 location(s) · The Netherlands Cancer Institute · NCT06342037A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
Phase 1/Phase 2 · 14 location(s) · Volastra Therapeutics, Inc. · NCT05902988Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and B
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT05064280Induction Therapy of PTX+BV Followed by Atezolizumab+Nab-PTX for PD-L1+ TNBC
Phase 2 · 1 location(s) · Japan Breast Cancer Research Group · NCT06793553A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC)
Phase 1/Phase 2 · 1 location(s) · Shenzhen Majory Biotechnology Co., Ltd. · NCT07208149Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Andr
Phase 3 · 1 location(s) · Fudan University · NCT05954442Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
Phase 2 · 15 location(s) · Dana-Farber Cancer Institute · NCT04468061Tislelizumab Combined with Nab-Paclitaxel for First-Line Treatment of Advanced Triple-Negative Breast Cancer with Bone M
Phase 2 · 1 location(s) · Zhejiang Cancer Hospital · NCT06538896Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Phase 1/Phase 2 · 13 location(s) · Exscientia AI Ltd., a wholly owned subsidiary of Recursion P · NCT05985655Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07486089Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells
Phase 1 · 1 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT06347068Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)
Phase 1/Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT07011654Role of Axillary Lymph Node Dissection for Residual MACROMETASTASES After NEOADJUVANT Chemotherapy in Patients With HER2
Phase N/A · 1 location(s) · University Hospital, Basel, Switzerland · NCT07546695De-escalation of Neoadjuvant Chemotherapy Regimens With Immunotherapy Among TNBC
Phase N/A · 1 location(s) · Peking University People's Hospital · NCT06692725Sac-TMT Combined With Bevacizumab in TNBC With Brain Metastases
Phase 2 · 1 location(s) · Fudan University · NCT07623577
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.